Findings

What do systematic reviews say?

73 questions · 73 findings · 4 reviews · Infectious Diseases

Sort:Best matchNewest Highest certainty Download CSV

No studies found 14 · 19.2%GRADE not reported 7 · 9.6%Very low 31 · 42.5%Low 11 · 15.1%Moderate 6 · 8.2%High 4 · 5.5%

Fluoroquinolones vs beta‐lactams

Other adverse events clinical criteria · patients with Shigella dysentery

It is very uncertain whether fluoroquinolones changes other adverse events clinical criteria compared with beta‐lactams (very low certainty).

1 finding from 1 review

Antibiotic therapy for Shigella dysentery 2010 · Cochrane Headline outcomes only
RR 1.03 [0.77, 1.39]
4 studies · 570 participants
Very low

Fluoroquinolones vs macrolides

Diarrhoea · patients with Shigella dysentery

It is very uncertain whether fluoroquinolones changes diarrhoea on compared with macrolides (very low certainty).

1 finding from 1 review

Antibiotic therapy for Shigella dysentery 2010 · Cochrane Headline outcomes only
RR 0.6 [0.24, 1.49]
2 studies · 189 participants
Very low

Fluoroquinolones vs macrolides

Relapse ‐ not reported · patients with Shigella dysentery

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic therapy for Shigella dysentery 2010 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fluoroquinolones vs macrolides

Serious adverse events ‐ not reported · patients with Shigella dysentery

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic therapy for Shigella dysentery 2010 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fluoroquinolones vs macrolides

Other adverse events clinical criteria · patients with Shigella dysentery

It is very uncertain whether fluoroquinolones changes other adverse events clinical criteria compared with macrolides (very low certainty).

1 finding from 1 review

Antibiotic therapy for Shigella dysentery 2010 · Cochrane Headline outcomes only
RR 1.33 [0.32, 5.56]
1 study · 76 participants
Very low

Fluoroquinolones vs beta‐lactams

Diarrhoea · patients with Shigella dysentery

It is very uncertain whether fluoroquinolones changes diarrhoea on compared with beta‐lactams (very low certainty).

1 finding from 1 review

Antibiotic therapy for Shigella dysentery 2010 · Cochrane Headline outcomes only
RR 1.03 [0.45, 2.37]
6 studies · 686 participants
Very low

Fluoroquinolones vs beta‐lactams

Relapse · patients with Shigella dysentery

It is very uncertain whether fluoroquinolones changes relapse ‐ All trials clinical criteria compared with beta‐lactams (very low certainty).

1 finding from 1 review

Antibiotic therapy for Shigella dysentery 2010 · Cochrane Headline outcomes only
RR 0.91 [0.11, 7.55]
3 studies · 357 participants
Very low

Fluoroquinolones vs beta‐lactams

Serious adverse events clinical criteria · patients with Shigella dysentery

It is very uncertain whether fluoroquinolones changes serious adverse events clinical criteria compared with beta‐lactams (very low certainty).

1 finding from 1 review

Antibiotic therapy for Shigella dysentery 2010 · Cochrane Headline outcomes only
RR 10.9 [0.61, 194.82]
1 study · 221 participants
Very low

Fluoroquinolones vs beta‐lactams

Discontinuation of medication due to adverse events · patients with Shigella dysentery

It is very uncertain whether fluoroquinolones changes adverse events leading to discontinuation of treatment compared with beta‐lactams (very low certainty).

1 finding from 1 review

Antibiotic therapy for Shigella dysentery 2010 · Cochrane Headline outcomes only
RR 1.02 [0.27, 3.89]
1 study · 127 participants
Very low

Cefixime vs fluoroquinolones

Clinical failure · adults and children with enteric fever

Cefixime may leads to higher clinical failure compared with fluoroquinolones (low certainty).

1 finding from 1 review

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins 2022 · Cochrane Headline outcomes only
RR 13.39 [3.24, 55.39]
2 studies · 240 participants
Low

Ceftriaxone vs fluoroquinolones

Clinical failure · adults and children with enteric fever

It is very uncertain whether ceftriaxone changes clinical failure compared with fluoroquinolones (very low certainty).

1 finding from 1 review

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins 2022 · Cochrane Headline outcomes only
RR 3.77 [0.72, 19.81]
4 studies · 359 participants
Very low

Ceftriaxone vs fluoroquinolones

Microbiological failure · adults and children with enteric fever

It is very uncertain whether ceftriaxone changes microbiological failure compared with fluoroquinolones (very low certainty).

1 finding from 1 review

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins 2022 · Cochrane Headline outcomes only
RR 1.65 [0.4, 6.83]
3 studies · 316 participants
Very low

Ceftriaxone vs fluoroquinolones

Relapse · adults and children with enteric fever

It is very uncertain whether ceftriaxone changes relapse compared with fluoroquinolones (very low certainty).

1 finding from 1 review

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins 2022 · Cochrane Headline outcomes only
RR 0.95 [0.31, 2.92]
3 studies · 297 participants
Very low

Ceftriaxone vs fluoroquinolones

Time to defervescence · adults and children with enteric fever

It is very uncertain whether ceftriaxone changes time to defervescence compared with fluoroquinolones (very low certainty).

1 finding from 1 review

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins 2022 · Cochrane Headline outcomes only
MD 2.73
3 studies · 285 participants
Very low

Ceftriaxone vs fluoroquinolones

Length of hospital stay · adults and children with enteric fever

1 finding from 1 review

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 47 participants
Low

Cefixime vs fluoroquinolones

Microbiological failure · adults and children with enteric fever

Cefixime showed no clear difference in microbiological failure compared with fluoroquinolones (low certainty).

1 finding from 1 review

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins 2022 · Cochrane Headline outcomes only
RR 4.07 [0.46, 36.41]
2 studies · 240 participants
Low

Ceftriaxone vs fluoroquinolones

Convalescent faecal carriage · adults and children with enteric fever

It is very uncertain whether ceftriaxone changes convalescent faecal carriage compared with fluoroquinolones (very low certainty).

1 finding from 1 review

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins 2022 · Cochrane Headline outcomes only
RR 0.18 [0.01, 3.72]
1 study · 73 participants
Very low

Ceftriaxone vs fluoroquinolones

Serious adverse events · adults and children with enteric fever

The review found no eligible studies for this question.

1 finding from 1 review

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cefixime vs fluoroquinolones

Relapse · adults and children with enteric fever

Cefixime may leads to higher relapse compared with fluoroquinolones (low certainty).

1 finding from 1 review

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins 2022 · Cochrane Headline outcomes only
RR 4.45 [1.11, 17.84]
2 studies · 220 participants
Low

Cefixime vs fluoroquinolones

Time to defervescence · adults and children with enteric fever

Cefixime may leads to higher time to defervescence compared with fluoroquinolones (low certainty).

1 finding from 1 review

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins 2022 · Cochrane Headline outcomes only
MD 1.74 [0.5, 2.98]
3 studies · 425 participants
Low